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Background: Measure Yourself Medical Outcome Profile (MYMOP) is a patient-generated outcome instrument
capable of measuring effects from a wide range of health care interventions. This paper reports the translation of
this instrument into German (MYMOP-D) and the assessment of validity and sensitivity to change for the MYMOP-D.
The instrument was piloted in a German primary care context.
Methods: The translation process was conducted according to international guidelines. Recruited patients of both
general practitioners and non-medical Complementary and Alternative Medicine (CAM) practitioners (“Heilpraktiker”)
in the German state of Baden-Wuerttemberg completed a questionnaire comprised of the MYMOP-D and the
EQ-5D. Responses were analysed to assess construct validity. For assessing the instrument’s sensitivity to change,
patients received the MYMOP-D again after four weeks at which point they were also asked for their subjective
views on change of symptoms. Correlation between MYMOP-D and EQ-5D and sensitivity to change as gradient in
score change and as standardized response mean (SRM) were calculated.
Results: 476 patients from general practices and 91 patients of CAM practitioners were included. Construct
validity of the MYMOP-D was given with a correlation of r = .47 with the EQ-5D. Sensitivity to change for
subjective change of symptoms could only be analysed for improvement or no change of symptoms, as only
12 patients reported deterioration of symptoms. Results showed the expected smooth gradient with 2.2, 1.3,
and 0.5 points of change for large, little improvement and no change, respectively. SRM for MYMOP-D Profile
Score was 0.88.
Conclusions: The MYMOP-D shows excellent construct validity. It is able to detect changes when symptoms in
patients improve or remain unchanged. Deterioration of symptoms could not be evaluated due to too few data.
With its brevity and simplicity, it might be an important tool for enhancing patient-centred care in the German
health care context.
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Patient-reported outcomes (PROs) are important tools for
enhancing patient-centred care. Increasingly, initiatives are
being set up in different sectors of health care to drive
forward the development and the use of PRO measures
(PROMs). Such initiatives to date have been in different
fields of medicine including oncology, surgery and rheuma-
tology, with a focus mostly on disease-specific tools [1-3].
Furthermore, established standardized instruments such as
the Short Form 36 (SF-36), EQ-5D or WHOQOL-BREF
[4] assess general health status or quality of life. However,
according to Lloyd et al., who have recently published a re-
view on PROMs, a simple set of questions that asks pa-
tients to assess outcomes of treatment can be time and
resource efficient in comparison to administering lengthy
measures [5].
Although it is not a single-item outcome, a similar
brief approach is pursued with the Measure Yourself
Medical Outcome Profile (MYMOP) [6]. This 4-item in-
strument allows patients themselves to nominate up to
two symptoms that are concerning them most, and to
subjectively assess the change of these symptoms over
time following a therapeutic intervention. The MYMOP
was developed by Paterson and initially published in 1996
[6], a revised version including items on medication was
validated in 1999 [7,8]. Since then, the MYMOP has been
used in several studies and has proven to be a sensitive
measure of within-person change over time [8,9]. In 2010,
the MYMOP was translated to a valid and change-sensitive
Chinese version [10]. Studies evaluating the MYMOP have
shown its good content validity [11], feasibility [12], and
sensitivity to change [13,14]. Although MYMOP has been
mostly implemented in studies in the field of Complemen-
tary and Alternative Medicine (CAM), it is capable of
measuring effects from a wide variety of health care inter-
ventions and is more sensitive to change than the SF-36 in-
strument [6]. Due to its brevity and simplicity, it can be
easily incorporated in other research settings including
primary care.
The aim of this study was, therefore, to translate the
MYMOP into German and pilot its use in a primary care
setting. Validation of the translated version focused on
construct validity and sensitivity to change.
Methods
Instrument and translation
The MYMOP consists of four questions. In the first two
questions, patients are asked to specify up to two symp-
toms which have concerned them most during the last
week. A third question asks for a restriction of an ADL
due to the symptom(s). The fourth question focuses on
general wellbeing. In an optional follow-up form, the
symptoms and activities specified in the initial form are
assessed again. Additionally, patients can choose to nameand rate a third symptom that newly occurs and is import-
ant to them now. In terms of scoring, all questions (symp-
toms, activity, and general wellbeing) have to be rated on
7-point Likert-type scales with 0 as the best and 6 as the
worst answer option. MYMOP Profile Scores can be cal-
culated as a mean of the ratings. These have values be-
tween 0 and 6; the higher the score, the worse the
outcome. In the initial form, up to four items are used for
scoring. In the follow-up form, up to five items are used
for scoring. Profile Scores of initial and follow-up forms
can be compared.
The German translation was based on the version
MYMOP2 (both initial and follow-up form). This is avail-
able free of charge on-line (http://www.bris.ac.uk/primary-
healthcare/resources/mymop). In keeping with established
international guidelines [15], in a first step, the MYMOP
was independently translated from English to German
(forward translation) by two researchers with German as
their mother-tongue. Both researchers agreed on a final
first German version. The translated German version was
given to a small patient sample (n = 16) to correct for am-
biguities and to ensure practicability. Due to their feed-
back, the questionnaire had to be slightly adjusted. The
final version was subsequently translated back into English
again (reverse “back” translation) by a colleague whose
mother-tongue is English and a second professional trans-
lator. The research team consented to the final reverse
translation version. This version was sent to the original
author of the MYMOP (C. Paterson), for final approval,
which was also received.
Validation
Objectives of the translated instrument validation process
were to assess (1) construct validity and (2) sensitivity
to change.
Setting and sampling
From February 2012 to July 2013, the MYMOP-D was
piloted with both patients from general practices and
patients seeing independent CAM health practitioners
(“Heilpraktiker”) in the German state of Baden-
Württemberg. Patients > 18 years who contacted the
practitioner with a newly developed symptom on a
given day that consented to participate in the study
were included. Patients with an insufficient command
of German, middle- or higher-grade dementia patients,
and patients who contacted the practitioner for a rea-
son other than a medical consultation (i.e. follow-up
prescription) were excluded from the study.
To reach a sufficient patient sample for validation and for
the expected correlation (r = .30, alpha = .05, 1-beta = .20),
our target sample was at least 85 patients. 779 general prac-
titioners and 150 CAM health practitioners were invited to
participate in the study. Addresses from general practices
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Statutory Health Insurance Physicians (Kassenärztliche
Vereinigung). Addresses for CAM health practitioners
were collected from telephone books.Data collection
In general practices, patients were approached by a doc-
toral student from the Department of General Practice
and Health Services Research (KK, KhH) while they were
waiting for their appointment. Patients were informed
about the study purpose by the doctoral student. Eligibility
to participate was documented by the physicians. When
filling out the questionnaire, patients could use a separate
room and consider their answers undisturbed.
This procedure was not feasible for the patients of the
CAM health practitioners; as the number of consulting
patients per day was far less compared to that in GP
practices, so that the continuous presence of the doc-
toral student could not be guaranteed. Therefore, we
elected to train the participating CAM practitioners in
informing patients on the study purpose and handing
out the MYMOP-D. They were advised to approach pa-
tients consecutively and were provided with a screening
list with possible reasons for excluding patients.
Participating patients noted their address on the ques-
tionnaire thus enabling a follow-up assessment after
4 weeks. Patients received the follow-up questionnaire
via mail and could return it in a postage-paid envelope.
Returned questionnaires were given a pseudonym num-
ber before all personal information was erased.Table 1 Participant characteristics (n = 567)
Gender n (%)
Female 368 (64.9)
Male 199 (35.1)
Age M (SD) 50.1 (17.9) yearsInstruments for validation
To assess construct validity, a comparison with a
quality-of-life questionnaire was applied. In contrast to
Paterson who used the SF-36 [6], we decided to use the
EQ-5D as it takes less time to complete and both mea-
sures are comparable [16]. The EQ-5D consists of 5
items with 3 statements each. Patients need to decide
which of the 3 statements best fits their physical and
mental state. Out of the 5 answers, an index score can
be calculated [17]; the higher the score, the better the
patient’s quality of life.
To assess sensitivity to change, patients had to evalu-
ate the severity of symptoms at the 4-week follow-up
compared with at the time of the initial assessment.
They were asked to answer the question: “Please indi-
cate how your symptoms have been in general during
the last 4 weeks, since the initial assessment.” with the
answer options being “much better”, “a little better”,
“unchanged”, “a little worse”, and “much worse”. Due to
organizational problems, this question was later in-
cluded in follow-up questionnaires in September 2012.Data analysis
In a first step, patients from general practices and patients
of CAM health practitioners were compared regarding
their socio-demographic characteristics to facilitate a rea-
sonable joint analysis of both groups. Described symptoms
were categorized using the second edition of the Inter-
national Classification of Primary Care (ICPC-2) [18]. For
analysis of construct validity, MYMOP-D Profile Scores
and EQ-5D scores were correlated. To confirm construct
validity, a correlation of r > =.30 was expected (based on
the results of Paterson [6]). Since higher scores denote
worse outcome in the MYMOP-D and better outcome in
the EQ-5D, the correlation was expected to be negative in
tendency. For sensitivity to change, standardized response
means (SRM) were calculated [6,19]. Additionally, the
mean changes in the MYMOP-D were compared among
the different categories of patient-rated perceived change in
severity of symptoms. A smooth gradient from deterior-
ation to improvement is to be expected. ANOVA was used
for the detection of differences in changes between groups.
For all statistical analyses, IBM SPSS version 20 was
used.
The study protocol was approved by the ethics commit-
tee of the Medical Faculty of the University of Heidelberg
(S-443/2011).
Results
Study sample
567 participants (476 patients from 34 general practices
and 91 patients from 11 CAM practices) were included
in our study and completed the initial questionnaire.
Characteristics of the sample are to be found in Table 1.
Due to optional questions and missing values in single
questions, the sample size in the analyses varies slightly.
Valid “n” are reported in the tables. Mean initial values
of MYMOP-D profile score, of ratings of symptoms, ac-
tivity and wellbeing, and of the EQ-5D scores are to be
found in Table 2. Reported symptoms covered all chap-
ters of the ICPC2 (except W: Pregnancy, Childbearing,
Family Planning, and Y: Male Genital); most commonly
reported symptoms were back pain, cough and fatigue.
From 341 patients of the 567 patients (60.1%), we re-
ceived a completed follow-up questionnaire. Patients
who returned the questionnaire were more likely female
(p = .02) and on average 6 years older than patients who
did not fill out the follow-up form (responders M = 52.5,
SD = 17.5; non-responders M = 46.3, SD = 17.8; p < .01).
Table 2 MYMOP-D and EQ-5D
All (n = 567)
MYMOP-D Mean (SD) Valid n
Symptom 1 3.9 (1.4) 565
Symptom 2 3.9 (1.3) 418
Activity 4.1 (1.5) 550
Wellbeing 3.1 (1.4) 565
Profile score 3.7 (1.1) 564
Duration of symptom 1 n (%) 566
0-4 weeks 176 (31.0)
4-12 weeks 63 (11.1)
3 months – 1 year 76 (13.4)
1-5 years 103 (18.2)
>5 years 148 (26.1)
Medication for symptoms 318 (56.1) 567
Medication in general n (%) 564
None 105 (18.5)
1-2 231 (40.7)
3-4 127 (22.4)
5-6 53 (9.3)
7 and more 48 (8.5)
EQ-5D M (SD)
Health assessment on VAS 64.4 (20.3) 565
Index score 0.79 (0.23) 557
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sponders and non-responders to follow-up, except for
activity (responders M = 4.0, SD = 1.6; non-responders
M = 4.3, SD = 1.4; p = .03).Validity
For a total of 554 patients, both MYMOP-D profile score
and EQ-5D index score could be calculated for the initial
completion of the questionnaire. For 13 patients, scores
could not be computed due to missing values. MYMOP-D
and EQ-5D correlated significantly and higher than
expected with r = −.47 (p < .01).Sensitivity to change
On average, symptoms improved from initial to follow-
up assessment based on subjective reporting via the
MYMOP-D (Table 3). With the exception of the question
on wellbeing, all MYMOP-D questions and the Profile
Score had SRM > .80, indicating large effects of sensitivity
to change [19], and wellbeing showing weak sensitivity to
change with an SRM= 0.43. The EQ-5D index and the
VAS in comparison showed a sensitivity to change of
SRM= 0.35 and 0.17, respectively.From the total of 341 patients, who returned the follow-
up questionnaire, 161 also rated the change of symptoms
they perceived on the single question with answer options
from “much better” to “much worse”. There were no dif-
ferences in age and gender between patients who gave an
overall assessment of their perceived change of symptoms
and those who did not answer this question. Twelve pa-
tients (7.5%) reported deterioration of their symptoms; for
47 patients (29.2%) symptoms remained at the same level,
and for 102 patients (63.4%) symptoms improved. For pa-
tients whose symptoms were subjectively “much better”,
mean MYMOP-D scores on the profile score and all ques-
tions except wellbeing decreased (signifying improvement)
by at least 2 points (Table 4, Figure 1). MYMOP-D scores
of patients with symptoms which were subjectively “a little
better” improved on average between 0.8 and 1.9 points
(Table 4, Figure 1). Patients with unchanged symptoms re-
ported mean differences between 0.0 and 0.8 points on the
MYMOP-D (Table 4, Figure 1). The small sample of pa-
tients with subjectively worse symptoms consists of 10 pa-
tients reporting “a little worse” symptoms and 2 patients
reporting “much worse” symptoms. Mean differences of
this sample did not follow the smooth gradient; results are
given in Table 4.
Discussion
The MYMOP2 is a patient-oriented instrument; patients
themselves state problem symptoms in their own words. It
is applicable to primary care since the symptoms can still
be classified using the ICPC2. It can also be used in CAM
settings, which is of growing importance to patients (not
only in Germany). The MYMOP2 has been used success-
fully in English-speaking countries and until now there
was no validated German translation available. Based on
the results of this study, the German version of the Meas-
ure Yourself Medical Outcome Profile, the MYMOP-D,
proved to be both valid and sensitive to change. For con-
struct validity, a high concordance of MYMOP-D and
EQ-5D could be shown in our sample. High standardized
response means after 4 weeks are reflected in a large pro-
portion of patients who reported improved symptoms. Re-
sults also showed the expected smooth gradient in all
questions and the MYMOP-D profile score for patients
reporting unchanged and improved symptoms.
The correlation between MYMOP-D and EQ-5D was
higher than expected on the basis of the original valid-
ation study [6]. We used the EQ-5D instead of the SF-36
that Paterson [6] and Chung et al. [10] used. Models
mapping the SF-36 onto the EQ-5D showed similar re-
sults [16], so that our results are comparable to other
validated versions of the MYMOP.
Sensitivity to change as measured as standardized re-
sponse means is comparable to other studies using the
MYMOP [6,14]. Patients in our study reported large effects
Table 3 Mean change in MYMOP-D scores and standardized response mean (SRM)
Mean (SD) score at
initial administration
Valid n Mean (SD) score
at follow-up
Valid n Mean (SD) change Valid n SRM
MYMOP-D profile score 3.7 (1.1) 564 2.3 (1.3) 332 1.3 (1.5) 331 0.88
Symptom 1 3.9 (1.4) 565 2.4 (1.5) 337 1.5 (1.8) 337 0.80
Symptom 2 3.9 (1.3) 418 2.4 (1.5) 256 1.5 (1.7) 242 0.83
Activity 4.1 (1.5) 550 2.2 (1.8) 330 1.7 (2.0) 325 0.84
Wellbeing 3.1 (1.4) 565 2.3 (1.3) 335 0.7 (1.7) 334 0.43
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high proportion of patients also reporting a subjective im-
provement of their symptoms. The EQ-5D, in comparison,
was less able to detect changes in patients’ experiences of
their symptoms. In a review considering different patient
groups, SRMs of the EQ-5D were also weak with valuesTable 4 Sensitivity to change of the MYMOP-D profile
score depending on patient-rated perceived change of
symptoms
Patient-rated perceived
change of symptoms
Mean (SD) change in
score (initial – follow-up)
No. of patients
Symptom 1 160
Much bettera,b,c 2.7 (1.5) 55
A little betterd 1.3 (1.4) 46
Unchangedd 0.8 (1.4) 47
Worsed 0.8 (1.8) 12
Symptom 2 128
Much bettera,b,c 2.5 (1.9) 45
A little betterb,d 1.5 (1.3) 37
Unchangedc,d 0.4 (1.3) 36
Worsed 0.6 (1.1) 10
Activity 154
Much betterb 2.7 (2.0) 53
A little better 1.9 (1.6) 46
Unchangedd 0.8 (1.9) 43
Worse 1.3 (1.9) 12
Wellbeing 159
much betterb 1.2 (1.6) 55
A little better 0.8 (1.6) 47
Unchangedd 0.0 (1.4) 45
Worse 0.1 (1.2) 12
MYMOP-D profile score 158
Much bettera,b,c 2.2 (1.2) 55
A little betterb,d 1.3 (1.2) 46
Unchangedc,d 0.5 (1.0) 45
Worsed 0.7 (1.1) 12
Significant differences (Bonferroni correction) to aworse, bunchanged, ca little
better, dmuch better.not larger than .43 after 3 to 12 months [20]. It seems the
EQ-5D only reacts to major impacts on quality of life.
The MYMOP-D profile score and all questions except
the one regarding wellbeing were very sensitive to change.
Other studies using the MYMOP also observed the ques-
tion about wellbeing as the least sensitive of the questions
[6,14,21]. Wellbeing is influenced by a multitude of factors
and reported symptoms at a given point in time might be
just a (minor) part of it. The MYMOP allows patients to
name other factors they suspect have an influence on their
health, but patients – at least in our study – rarely use this
opportunity. In a clinical setting, as a tool for communica-
tion and reflecting on the therapy with the patient [6], we
recommend that they should be encouraged to fill out this
part of MYMOP as well. It enables medical professionals to
understand patients’ underlying concepts of disease and
could assist in identifying influences on wellbeing. Never-
theless, the practicability of the MYMOP-D as a communi-
cation tool in everyday general practice and with patients of
CAM health practitioners remains to be demonstrated.
Baseline values and change in MYMOP-D scores are
comparable to the results of other studies with patients,
such as: from an acupuncture clinic [9], with rotator
cuff tendinitis [22], with long-term conditions [13], or
with insomnia [23]. With this background, it would be
possible to conclude clinically relevant improvements
from the MYMOP scores. For a clinical consultation,
this could help both practitioners and patients to define
appropriate therapy goals.Figure 1 Sensitivity to change of the MYMOP-D profile score
depending on patient-rated perceived change of symptoms.
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chronic low back pain advised the use of more specific in-
stead of generic tools for measuring sensitivity to change
[24]; an evaluation based on patient preference, i.e. with
the MYMOP-D, is highly specific. The use of patient-
preference questionnaires has several advantages: patients
only rate symptoms and activities which are of immediate
meaning to them, and since contents of the questionnaire
are personally relevant, the problem of missing data is mini-
mized. Improvements during therapy are easier to detect.
Limitations of the study
Although adequate numbers of patients returned the follow-
up questionnaire, only a part of this number had answered
the question about the perceived change of symptoms. Too
few patients reported a deterioration to be able to calculate
sensitivity to change in this category. The problem with only
a small proportion of patients reporting deterioration has
been previously observed [9,10] and discussed [12]. The fact
is patients presenting with acute symptoms for medical ad-
vice, very rarely experience worsening symptoms four week
later (and even more rarely do these patients develop
chronic symptoms of disease) [12]. In our study, all patients
were under current treatment for their symptom(s). Add-
itionally, the main problem for the patient might change
over time and is not considered in this questionnaire [11].
Conclusions
The MYMOP-D proved to be a valid tool with good sensi-
tivity to change and with excellent construct validity. For
sensitivity to change over the whole spectrum, including
deterioration of symptoms, more patients with deteriorat-
ing symptoms need to be assessed. Because of its brevity
and simplicity, it can be easily incorporated into primary
health care settings and, therefore, might be an important
tool to enhance patient-centred care.
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